Cancer Genetics and Therapeutic Opportunities in Urologic Practice
Open Access
- 17 March 2020
- Vol. 12 (3), 710
- https://doi.org/10.3390/cancers12030710
Abstract
This article aims to summarize the current literature on genetic alterations related to tumors of the genitourinary tract. Novel associations have recently been reported between specific DNA alterations and genitourinary malignancies. The most common cause of chromosome 3p loss in clear cell renal cell carcinoma is a chromothripsis event, which concurrently generates a chromosome 5q gain. Specific patterns of clear cell renal cell carcinoma metastatic evolution have been uncovered. The first therapy targeting a specific molecular alteration has now been approved for urothelial carcinoma. Germline mutations in DNA damage repair genes and the transcription factor HOXB13 are associated with prostate cancer and may be targeted therapeutically. The genetic associations noted across different genitourinary cancers can inform potential screening approaches and guide novel targeted treatment strategies.This publication has 106 references indexed in Scilit:
- Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European expertsGut, 2013
- Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeuticsGenome Research, 2012
- Germline BRCA1 mutations increase prostate cancer riskBritish Journal of Cancer, 2012
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and MortalityJAMA, 2010
- Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriersJournal of Medical Genetics, 2010
- Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2Proceedings of the National Academy of Sciences of the United States of America, 2009
- The role of the Birt–Hogg–Dubé protein in mTOR activation and renal tumorigenesisOncogene, 2009
- The Role of the BRCA2 Gene in Susceptibility to Prostate Cancer RevisitedCancer Epidemiology, Biomarkers & Prevention, 2008
- Kidney-Targeted Birt-Hogg-Dube Gene Inactivation in a Mouse Model: Erk1/2 and Akt-mTOR Activation, Cell Hyperproliferation, and Polycystic KidneysJNCI Journal of the National Cancer Institute, 2008
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesAmerican Journal of Human Genetics, 2003